A randomized, double‐blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short‐ and long‐term efficacy and safety results

Abstract

Objective. In an international, multicenter, double-blind, randomized clinical trial we evaluated the short-term (3 months) and long-term (12 months) efficacy and safety of 2 different doses of meloxicam oral suspension compared with the efficacy and safety of naproxen oral suspension in children with oligoarticular-course (oligo-course) or polyarticularcourse (poly-course) juvenile idiopathic arthritis (JIA).Methods. Children ages 2-16 years who had active oligo-course or poly-course JIA and who required therapy with a nonsteroidal antiinflammatory drug were eligible for this trial. Patients were randomly allocated to receive therapy with meloxicam oral suspension, 0.125 mg/kg body weight in a single daily dose; meloxicam oral suspension, 0.25 mg/kg body weight in a single daily dose; or naproxen, 10 mg/kg body weight in 2 daily doses. The trial drugs were administered in a double-blind, double-dummy design for up to 12 months. Response rates were determined according to the American College of Rheumatology pediatric 30% improvement criteria (ACR pediatric 30). Safety parameters were assessed by evaluating the frequency of adverse events in the 3 groups.Results. Of 232 patients enrolled, 225 received treatment, 6 were not eligible for randomization, and 1 randomized patient was not treated. One hundred eighty-two patients (81%) completed the 12-month treatment period. Response rates according to the ACR pediatric 30 criteria improved from month 3 to month 12, as follows: from 63% to 77% in the meloxicam 0.125 mg/kg group, from 58% to 76% in the meloxicam 0.25 mg/kg group, and from 64% to 74% in the naproxen group. No statistically significant differences in reSupported by a grant to

Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy

“…In general, discontinuations due to clinical AEs occur in higher proportions of patients during trials evaluating long-term therapy with analgesic medications. 17,18 The proportion of patients that discontinued due to an AE in this study is similar to proportions seen in other trials of long duration that evaluate analgesic treatments. Furthermore, the discontinuation rate may be also reflective of the comorbidity of patients with hemophilic arthropathy, since a large percentage of these patients have serious secondary diagnoses such as HIV or hepatitis C infections as well as the primary disease of hemophilia.…”

A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis

“…The ACR Pedi 30 criteria have been validated, and their reliability in discriminating between active agent and placebo has been established in studies of NSAIDs (24,25), MTX (6), etanercept (8), and more recently, other biologic agents (26,27). We believe the lack of statistical significance between treatment groups in the present study resulted from the combination of a small sample size (60 patients per treatment group) and a higher-than-anticipated rate of response (49.2%) in the placebo group (28), which was likely due to a greater placebo effect associated with agents administered by infusion and a placebo treatment phase that was too brief.…”

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

“…The CHAQ is well established for the use in children with JIA (14) and is used as one of six core response variables in clinical drug trials (15)(16)(17)(18)(19)(20). It has been validated and evaluated in the German language (21).…”